Stock Track | PTC Therapeutics Soars 5.28% Pre-Market on Strong Earnings, Promising Pipeline Updates and Bullish Analyst Views

Stock Track

02-28

PTC Therapeutics (PTCT) stock soared 5.28% in the pre-market trading session on Friday, following the release of the company's strong financial results for 2024 and encouraging updates on its promising drug pipeline.

The biopharmaceutical company reported impressive financial performance for the fourth quarter and full year 2024, exceeding expectations. Highlights included:

Q4 revenue of $213 million and full year 2024 revenue of $807 million, surpassing guidance.
Cash position of over $1.1 billion at the end of 2024, further bolstered by a $1 billion upfront payment from Novartis in January 2025.
Strong performance from the company's DMD franchise, which generated $547 million in revenue for the full year 2024.

Additionally, PTC Therapeutics provided promising updates on its drug pipeline, including:

Achieving all clinical and regulatory milestones on schedule in 2024, with four FDA approval applications, one already approved and others under review.
Preparing for multiple potential product launches in 2025, including sepiapterin for PKU and vatiquinone for Friedreich's ataxia, which could significantly enhance their commercial portfolio.
Positive developments in the PTC518 Huntington's disease program, including a global development and commercialization collaboration with Novartis.

Analysts have also expressed optimism about PTC Therapeutics' prospects. William Blair's Sami Corwin and JP Morgan's Eric Joseph both reiterated their "Buy" ratings, citing the company's strong commercial foundation, strategic partnerships, and promising clinical catalysts.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1167719461"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1167719461\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1167719461?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 22:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167719461","market":"hk","top_or_hot":-1,"title":"Stock Track | PTC Therapeutics Soars 5.28% Pre-Market on Strong Earnings, Promising Pipeline Updates and Bullish Analyst Views","media":"Stock Track","content":"<p>PTC Therapeutics (PTCT) stock soared 5.28% in the pre-market trading session on Friday, following the release of the company's strong financial results for 2024 and encouraging updates on its promising drug pipeline.</p>\n\n<p>The biopharmaceutical company reported impressive financial performance for the fourth quarter and full year 2024, exceeding expectations. Highlights included:\n<ul>\n<li>Q4 revenue of $213 million and full year 2024 revenue of $807 million, surpassing guidance.</li>\n<li>Cash position of over $1.1 billion at the end of 2024, further bolstered by a $1 billion upfront payment from Novartis in January 2025.</li>\n<li>Strong performance from the company's DMD franchise, which generated $547 million in revenue for the full year 2024.</li>\n</ul>\n</p>\n\n<p>Additionally, PTC Therapeutics provided promising updates on its drug pipeline, including:\n<ul>\n<li>Achieving all clinical and regulatory milestones on schedule in 2024, with four FDA approval applications, one already approved and others under review.</li>\n<li>Preparing for multiple potential product launches in 2025, including sepiapterin for PKU and vatiquinone for Friedreich's ataxia, which could significantly enhance their commercial portfolio.</li>\n<li>Positive developments in the PTC518 Huntington's disease program, including a global development and commercialization collaboration with Novartis.</li>\n</ul>\n</p>\n\n<p>Analysts have also expressed optimism about PTC Therapeutics' prospects. William Blair's Sami Corwin and JP Morgan's Eric Joseph both reiterated their \"Buy\" ratings, citing the company's strong commercial foundation, strategic partnerships, and promising clinical catalysts.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | PTC Therapeutics Soars 5.28% Pre-Market on Strong Earnings, Promising Pipeline Updates and Bullish Analyst Views</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | PTC Therapeutics Soars 5.28% Pre-Market on Strong Earnings, Promising Pipeline Updates and Bullish Analyst Views\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-28 22:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PTC Therapeutics (PTCT) stock soared 5.28% in the pre-market trading session on Friday, following the release of the company's strong financial results for 2024 and encouraging updates on its promising drug pipeline.</p>\n\n<p>The biopharmaceutical company reported impressive financial performance for the fourth quarter and full year 2024, exceeding expectations. Highlights included:\n<ul>\n<li>Q4 revenue of $213 million and full year 2024 revenue of $807 million, surpassing guidance.</li>\n<li>Cash position of over $1.1 billion at the end of 2024, further bolstered by a $1 billion upfront payment from Novartis in January 2025.</li>\n<li>Strong performance from the company's DMD franchise, which generated $547 million in revenue for the full year 2024.</li>\n</ul>\n</p>\n\n<p>Additionally, PTC Therapeutics provided promising updates on its drug pipeline, including:\n<ul>\n<li>Achieving all clinical and regulatory milestones on schedule in 2024, with four FDA approval applications, one already approved and others under review.</li>\n<li>Preparing for multiple potential product launches in 2025, including sepiapterin for PKU and vatiquinone for Friedreich's ataxia, which could significantly enhance their commercial portfolio.</li>\n<li>Positive developments in the PTC518 Huntington's disease program, including a global development and commercialization collaboration with Novartis.</li>\n</ul>\n</p>\n\n<p>Analysts have also expressed optimism about PTC Therapeutics' prospects. William Blair's Sami Corwin and JP Morgan's Eric Joseph both reiterated their \"Buy\" ratings, citing the company's strong commercial foundation, strategic partnerships, and promising clinical catalysts.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTCT","symbol_name":"PTC Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1167719461","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167719461","pubTimestamp":1740754648,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"PTC Therapeutics  stock soared 5.28% in the pre-market trading session on Friday, following the release of the company's strong financial results for 2024 and encouraging updates on its promising drug pipeline.The biopharmaceutical company reported impressive financial performance for the fourth quarter and full year 2024, exceeding expectations. Highlights included:. Q4 revenue of $213 million and full year 2024 revenue of $807 million, surpassing guidance.Cash position of over $1.1 billion at ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PTCT":"PTC Therapeutics Inc."},"translate_title":"股票跟踪PTC Therapeutics盘前飙升5.28%，原因是强劲的盈利、充满希望的产品线更新和看涨的分析师观点","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTCT":1},"content_text":"PTC Therapeutics (PTCT) stock soared 5.28% in the pre-market trading session on Friday, following the release of the company's strong financial results for 2024 and encouraging updates on its promising drug pipeline.\nThe biopharmaceutical company reported impressive financial performance for the fourth quarter and full year 2024, exceeding expectations. Highlights included:\n\nQ4 revenue of $213 million and full year 2024 revenue of $807 million, surpassing guidance.\nCash position of over $1.1 billion at the end of 2024, further bolstered by a $1 billion upfront payment from Novartis in January 2025.\nStrong performance from the company's DMD franchise, which generated $547 million in revenue for the full year 2024.\n\nAdditionally, PTC Therapeutics provided promising updates on its drug pipeline, including:\n\nAchieving all clinical and regulatory milestones on schedule in 2024, with four FDA approval applications, one already approved and others under review.\nPreparing for multiple potential product launches in 2025, including sepiapterin for PKU and vatiquinone for Friedreich's ataxia, which could significantly enhance their commercial portfolio.\nPositive developments in the PTC518 Huntington's disease program, including a global development and commercialization collaboration with Novartis.\n\nAnalysts have also expressed optimism about PTC Therapeutics' prospects. William Blair's Sami Corwin and JP Morgan's Eric Joseph both reiterated their \"Buy\" ratings, citing the company's strong commercial foundation, strategic partnerships, and promising clinical catalysts.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}